Strategy of Patient-Specific Therapeutics in Cardiovascular Disease Through Single-Cell RNA Sequencing

Yunseo Jung; Juyeong Kim; Howon Jang; Gwanhyeon Kim; Yoo-Wook Kwon

doi:10.4070/kcj.2022.0295

Strategy of Patient-Specific Therapeutics in Cardiovascular Disease Through Single-Cell RNA Sequencing

Korean Circ J. 2023 Jan;53(1):1-16. doi: 10.4070/kcj.2022.0295.

Authors

Yunseo Jung^#¹, Juyeong Kim^#², Howon Jang^#², Gwanhyeon Kim², Yoo-Wook Kwon^{1

3}

Affiliations

¹ Strategic Center of Cell and Bio Therapy for Heart, Diabetes & Cancer, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
² Department of Medicine, Seoul National University College of Medicine, Seoul National University, Seoul, Korea.
³ Department of Medicine, Seoul National University College of Medicine, Seoul National University, Seoul, Korea. ywkwon@snu.ac.kr.

^# Contributed equally.

Abstract

Recently, single cell RNA sequencing (scRNA-seq) technology has enabled the discovery of novel or rare subtypes of cells and their characteristics. This technique has advanced unprecedented biomedical research by enabling the profiling and analysis of the transcriptomes of single cells at high resolution and throughput. Thus, scRNA-seq has contributed to recent advances in cardiovascular research by the generation of cell atlases of heart and blood vessels and the elucidation of mechanisms involved in cardiovascular development and diseases. This review summarizes the overall workflow of the scRNA-seq technique itself and key findings in the cardiovascular development and diseases based on the previous studies. In particular, we focused on how the single-cell sequencing technology can be utilized in clinical field and precision medicine to treat specific diseases.

Keywords: Clinical application; Heart development; Precision medicine; Single cell RNA sequencing.

Publication types

Review